Tvardi Therapeutics (NASDAQ:TVRD – Get Free Report) and Eli Lilly and Company (NYSE:LLY – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.
Earnings & Valuation
This table compares Tvardi Therapeutics and Eli Lilly and Company”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Tvardi Therapeutics | N/A | N/A | -$18.21 million | ($2.79) | -0.58 |
| Eli Lilly and Company | $65.18 billion | 16.64 | $20.64 billion | $29.80 | 38.66 |
Volatility and Risk
Tvardi Therapeutics has a beta of 0.32, meaning that its share price is 68% less volatile than the S&P 500. Comparatively, Eli Lilly and Company has a beta of 0.5, meaning that its share price is 50% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current ratings for Tvardi Therapeutics and Eli Lilly and Company, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tvardi Therapeutics | 1 | 1 | 6 | 1 | 2.78 |
| Eli Lilly and Company | 1 | 3 | 25 | 1 | 2.87 |
Tvardi Therapeutics currently has a consensus price target of $18.00, indicating a potential upside of 1,011.11%. Eli Lilly and Company has a consensus price target of $1,304.86, indicating a potential upside of 13.26%. Given Tvardi Therapeutics’ higher probable upside, analysts clearly believe Tvardi Therapeutics is more favorable than Eli Lilly and Company.
Institutional and Insider Ownership
44.7% of Tvardi Therapeutics shares are owned by institutional investors. Comparatively, 82.5% of Eli Lilly and Company shares are owned by institutional investors. 7.4% of Tvardi Therapeutics shares are owned by insiders. Comparatively, 0.1% of Eli Lilly and Company shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares Tvardi Therapeutics and Eli Lilly and Company’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Tvardi Therapeutics | N/A | -145.40% | -91.11% |
| Eli Lilly and Company | 33.53% | 97.83% | 23.23% |
Summary
Eli Lilly and Company beats Tvardi Therapeutics on 11 of the 13 factors compared between the two stocks.
About Tvardi Therapeutics
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Receive News & Ratings for Tvardi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tvardi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
